Janus Serum Bank. Hilde Langseth MSc, PhD Senior Researcher and head of Janus Serum Bank Cancer Registry of Norway Department of Research

Transcription

1 Janus Serum Bank Hilde Langseth MSc, PhD Senior Researcher and head of Janus Serum Bank Cancer Registry of Norway Department of Research Biobank Conference March 13th 2018 Felix konferansesenter, Oslo

2 Oslo Cancer Cluster Innovation Park (OCCI) since 2015 Oslo University Hospital - Radium Hospital Institute for Cancer Research Cancer Registry of Norway 4-6 th floor Research Department and Janus laboratory

3 Biobank design Established in 1973 funded by the Norwegian Cancer Society Population-based cancer biobank Consist of more than pre diagnostic samples from ~ donors Average age at enrollment is 41 year The Janus Serum Bank was integrated into the Cancer Registry of Norway in 2004 The donors were recruited in national health screening surveys during the 1970s-90s, and from Red cross blood donors

4 Janus Biobank description Blood serum Diagnostic samples from Janus donors with cancer (1,1 %) Red Cross blood donors (10%) National health screening surveys (90%) Janus sample collections Baseline questionnaire Smoking habits BMI Physical activity Total Janus cohort n= W M Ref: Langseth et al, Cohort profile: The Janus Serum Bank Cohort in Norway, International Journal of Epidemiology, 2016, 1 9 doi: /ije/dyw027 Ref: Hjerkind et al, Cohort Profile update: The Janus Serum Bank Cohort in Norway, International Journal of Epidemiology, 2017, 1 8 doi: /ije/dyw302

5 Cases in thousands Cancer Statistics Cancer incidence in the Janus Cohort - follow-up Males Females Total The horizontal line represents start of sample collection

6 The five most common cancer types in the Janus Cohort Males Females

7 Clinical and Phenotypic data Biomarker data from Janus donors HPV Vit D levels Organoclorine RNA seqencing, metabolomic and proteomic data PSA, CA125, HE4 Ref: Langseth H et.al. Acta Oncologica 2010;49:

8 Research focus About 50 ongoing studies on more than 15 different cancer types, investigating biomarkers of exposure, effect, prognosis and susceptibility Lead investigators in studies of small non-coding RNA as early detection biomarkers of cancer, risk biomarkers of bladder cancer, environmental exposures (organochlorine) and cancer, as well as quality studies of serum components Research group special competence Very good expertise in biobank and register-based research High expertise in sample quality assurance and biobank management External and international collaborators Extensive collaboration with research groups at Oslo University Hospital and other national research groups (NTNU/HUNT, FHI, Akershus University Hospital, The Norwegian Prostate Cancer Biomarker Consortium) Participates in several international consortia and collaborates with a number of research groups internationally (National Cancer Institute (NCI), International Agency for Research on Cancer (IARC), German Cancer Research Center/DKFZ, Heidelberg University, Germany, Saarland University, Germany

9 Case-study - Small non-coding RNA and cancer Overall project aim: to investigate small non-coding RNA as early and potential screening biomarkers of cancer Achievements so far: We have developed a high throughput platform for small RNA sequencing and produced expression profiles from more than Janus samples from patients with colorectal, lung, testis, prostate, breast, gallbladder and ovarian cancer and a large group of healthy controls Profiled the natural variation in serum RNA (ref: Umu SU, RNA Biol Feb 1;15(2): doi: / Next steps: Use detailed cancer data to analyse sncrna profiles by histological subgroups and metastatic cancer Identify and validate top candidate sncrna as potential screening biomarkers in collaboration with clinicians

10 How to collaborate? Applicants fill out an online application form: A detailed scientific protocol must be enclosed At least one collaborating partner/co-author from the Cancer Registry and /or Janus Serum Bank must be appointed A scientific steering committee is evaluating all projects An approval from the Norwegian Regional Committee for Medical Research Ethics (REC) is required Contact: Janus@kreftregisteret.no